Search Results

Integrin antagonists promising for anti-angiogenesis therapy.

• Authors : Friedlander, Martin

Subjects: *INTEGRINS; *EYE diseases; *THERAPEUTICS

• Source: Ophthalmology Times. 11/1/2004, Vol. 29 Issue 21, p37-38. 2p.

Record details

β1 and β3 integrins use distinct pathways to regulate CLAN formation: researchers optimistic discovery will lead to future treatment for steroid-induced glaucoma.

• Authors : Groves, Nancy

• Source: Ophthalmology Times. 2007, Vol. 32, Issue 19, pages. 1

Record details

Integrin peptide therapy on horizon.

• Authors : Groves, Nancy

Subjects: INTEGRINS; RETINAL degeneration treatment; OLIGOPEPTIDES

• Source: Ophthalmology Times. 4/1/2012, Vol. 37 Issue 7, p59-59. 1p.

Record details

Outlook for integrin peptide therapy: early success in treating wet AMD, diabetic eye disease suggests future role for new agent.

• Authors : Kaiser, Peter K.

• Source: Ophthalmology Times. 2014, Vol. 39, Issue 8, pages. 3

Record details

Integrin antagonists promising for anti-angiogenesis therapy: approach may target proliferating vascular endothelial cells without touching mature blood vessels.

• Authors : Guttman, Cheryl

• Source: Ophthalmology Times. 2004, Vol. 29, Issue 21, pages. 37

Record details

Topical integrin antagonist seems effective for dry eye disease: study of twice-daily lifitegrast dosing for 1 year yields no unexpected adverse events.

• Authors : Charters, Lynda

• Source: Ophthalmology Times. 2015, pages. 2

Record details

Novel therapy targets integrin receptors: anti-angiogenic, vitreolytic mechanisms of action hold promise for vitreoretinal disease.

• Authors : Karageozian, Vicken

• Source: Ophthalmology Times. 2015, pages. 2

Record details

Integrin peptide yields positive outcomes for VMA, VMT in phase II trial: dual mechanisms of action appear to inhibit new blood vessel formation, reduce leakage.

• Authors : Caceres, Vanessa

• Source: Ophthalmology Times. 2015, pages. 1

Record details

Bl and B3 integrins use two distinct pathways to regulate CLAN formation.

• Authors : Groves, Nancy; Filla, Mark S.

Subjects: MEDICAL research; ACTIN; GLAUCOMA treatment

• Source: Ophthalmology Times. 10/1/2007, Vol. 32 Issue 19, p81-81. 2/3p.

Record details

Integrin peptide for AMD emerging: improvements persisted for 60 days off-treatment after three monthly loading doses.

• Authors : Nelson, Roxanne

• Source: Ophthalmology Times. 2013, Vol. 38, Issue 14, pages. 2

Record details